TEVA Q1 2019 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q1 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.3B-15.2% YoY

Gross Profit

$1.9B43.2% margin

Operating Income

$134M3.1% margin

Net Income

-$105M-2.4% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-5.8%

Cash Flow

Operating Cash Flow

$112M

Free Cash Flow

-$13M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$59.9B

Total Liabilities

$44.0B

Stockholders' Equity

$14.7B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.3B	$5.1B	-15.2%
Gross Profit	$1.9B	$2.3B	-21.0%
Operating Income	$134M	$1.5B	-91.2%
Net Income	-$105M	$1.1B	-110.0%

Revenue Segments

Distribution

$151M100%

Geographic Segments

North America

$1.6B57%

Europe

$1.3B43%